Does AI-assisted colonoscopy lower the risk of future advanced colon lesions?
The Long-term Effect of Artificial Intelligence-assisted Colonoscopy on Risk of Metachronous Advanced Colonic Lesion
This study will test whether using artificial intelligence during colonoscopy lowers the chance of developing advanced colonic lesions later in people who previously had polyps.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 404 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT07467928 on ClinicalTrials.gov |
What this trial studies
This is a prospective follow-up of patients who completed a randomized trial comparing AI-assisted and conventional colonoscopy, bringing them back for scheduled surveillance colonoscopy to detect metachronous advanced colonic lesions. Investigators will compare the prevalence of advanced lesions on surveillance exams between participants whose prior colonoscopy used AI and those whose prior exam was conventional. Patients with inflammatory bowel disease, prior colorectal cancer, bowel resection, or new severe comorbidities that make colonoscopy unsafe are excluded. The trial is conducted by The University of Hong Kong at Queen Mary Hospital using standard surveillance colonoscopy and polypectomy procedures to capture outcomes.
Who should consider this trial
Good fit: Ideal candidates are people who completed the original randomized trial comparing AI-assisted versus conventional colonoscopy, are due for surveillance colonoscopy, and do not have IBD, prior colorectal cancer, or bowel resection.
Not a fit: Patients with inflammatory bowel disease, a history of colorectal cancer or bowel resection, those with new severe comorbidities making colonoscopy unsafe, or people who were not part of the original trial are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, AI-assisted colonoscopy could reduce the number of advanced colonic lesions found at later surveillance and potentially lower future colorectal cancer risk.
How similar studies have performed: Multiple randomized trials have shown that AI-assisted colonoscopy increases adenoma detection rates, but long-term evidence that it reduces metachronous advanced lesions remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Eligible participants are those who were previously enrolled and completed our randomized controlled trial comparing AI-assisted and conventional colonoscopy Exclusion Criteria: * In addition to the baseline exclusion criteria of the index trial, patients who were found to have inflammatory bowel disease, colorectal cancer and underwent bowel resection would be excluded. Similar to index trial, patients who have developed severe comorbid illnesses that make surveillance colonoscopy and polypectomy unsafe, or become unable to provide informed consent for trial participation would also be excluded Index trial: Lui TK, Lam CP, To EW, Ko MK, Tsui VWM, Liu KS, et al. Endocuff With or Without Artificial Intelligence-Assisted Colonoscopy in Detection of Colorectal Adenoma: A Randomized Colonoscopy Trial. Am J Gastroenterol. 2024;119(7):1318-25
Where this trial is running
Hong Kong
- Queen Mary Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Thomas KL Clinical Assoicate Professor, MD
- Email: tkllui@hku.kh
- Phone: 852 + 97360997
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.